Publisher Correction: Longitudinal study on hippocampal subfields and glucose metabolism in early psychosis
Reetta-Liina Armio, Heikki Laurikainen, Tuula Ilonen, Maija Walta, Elina Sormunen, Arvi Tolvanen, Raimo K. R. Salokangas, Nikolaos Koutsouleris, Lauri Tuominen, Jarmo Hietala
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAmino Acid Enzymes and Metabolism · Diet and metabolism studies · Metabolism and Genetic Disorders
Correction to: Schizophrenia 10.1038/s41537-024-00475-z, published online 31 July 2024
In this article there was an error in Table 3(a), the value under the column “Estimated difference (mm^3^)” should be 87 instead of 870. The errors have been corrected in the HTML and PDF versions of the article.
Corrected Table 3
Table 3. a) Whole hippocampus volume pairwise between-group baseline comparison analysis of FEP, CHR and CTR, including age, sex, total intracranial volume and body mass index as covariates. b) Subregional post-hoc pairwise between-group baseline comparison analysis of FEP, CHR and CTR, including age, sex, total intracranial volume and BMI as covariates.a) VolumeContrast baselineEstimated difference (mm^3^)95% Confidence IntervalDFt-ratiopFDR corrected pp with exposureFDR corrected p with exposureWhole hippocampusCTR - CHR87−15.09 –1892021.6800.09440.09440.13060.1306Whole hippocampusCTR - FEP192103.50–2812024.274<0.0001<0.00010.00120.0035Whole hippocampusCHR - FEP1053.37–2072022.0370.04290.06440.11370.1306b) VolumeContrast baselineEstimated difference (mm^3^)95% Confidence IntervalDFt-ratiopFDR corrected pp with exposureFDR corrected p with exposureTailCTR - CHR27.2810.40–44.22023.1870.00170.01000.00220.0130TailCTR - FEP34.4419.78–49.12024.632<0.00010.00020.00010.0017TailCHR - FEP7.16−9.77–24.12020.8340.40530.42290.54660.5704PresubiculumCTR - CHR10.58−6.29–27.52021.2360.21770.34860.25620.4645PresubiculumCTR - FEP21.566.90–36.22022.9000.00410.01990.01880.0904PresubiculumCHR - FEP10.98−5.96–27.92021.2780.20260.34860.31420.4645SubiculumCTR - CHR8.90−7.97–25.82021.0400.29950.36260.36040.4645SubiculumCTR - FEP18.884.22–33.52022.5390.01190.04440.04420.1404SubiculumCHR - FEP9.97−6.96–26.92021.1610.24690.34860.35930.4645CA1CTR - CHR10.20−6.68–27.12021.1920.23470.34860.32150.4645CA1CTR - FEP31.4416.78–46.12024.229<0.00010.00040.00050.0062CA1CHR - FEP21.244.31–38.22022.4730.01420.04440.02960.1184Molecular LayerCTR - CHR10.72−6.16–27.62021.2520.21190.34860.25730.4645Molecular LayerCTR - FEP29.9815.32–44.62024.0320.00010.00060.00080.0062Molecular LayerCHR - FEP19.262.33–36.22022.2430.02600.06240.05270.1404GCMLDGCTR - CHR7.91−8.96–24.82020.9250.35630.38870.38710.4645GCMLDGCTR - FEP18.283.62–32.92022.4580.01480.04440.05230.1404GCMLDGCHR - FEP10.36−6.57–27.32021.2070.22900.24860.36780.4645CA2/3CTR - CHR4.26−12.62–21.12020.4980.61940.61940.68870.6887CA2/3CTR - FEP13.64−1.02–28.32021.8350.06800.14840.18120.3955CA2/3CHR - FEP9.38−7.55–26.32021.0920.27590.36260.41860.4784CA4CTR - CHR8.32−8.56–25.22020.9720.33210.37960.36640.4645CA4CTR - FEP17.22.54–31.92022.3140.02170.05780.07070.1695CA4CHR - FEP8.88−8.05–25.82021.0340.30220.36260.45800.4997CA Cornu ammonis, Molecular Layer Molecular Layer of the CA fields and subiculum, GCMLDG The Granule Cell and Molecular Layer of the Dentate Gyrus, FDR False discovery rate.*Total lifetime antipsychotic exposure (until baseline) included in the model.FEP First-episode psychosis patient.CHR Clinical high-risk patient.CTR Population control.*Total lifetime antipsychotic exposure included in the model.